ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2014-3-119-125ssmu-73Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEW AND LECTURESСОВРЕМЕННЫЙ ПОДХОД К ХИМИОЛУЧЕВОЙ ТЕРАПИИ ЗЛОКАЧЕСТВЕННЫХ ГЛИОМ ГОЛОВНОГО МОЗГАCURRENT APPROACHES TO CHEMORADIOTHERAPY FOR MALIGNANT GLIOMASЧойнзоновЕ. Л.ChoinzonovYe. L.

Чойнзонов Евгений Лхамацыренович, доктор медицинских нак, профессор, академик РАН, зав. отделением опухолей головы и шеи, директор НИИ онкологии СО РАМН

gribova79@mail.ruГрибоваО. В.GribovaO. V.

Грибова Ольга Вячеславовна, кандидат медицинских наук, старший начный сотрудникотделения радиологии

gribova79@mail.ruСтарцеваЖ. А.StartsevaZh. A.

Старцева Жанна Александровна, доктор медицинских нак, зав. отделением радиологии

gribova79@mail.ruРябоваА. И.RyabovaA. I.

Рябова Анастасия Игоревна, младший научныйсотрудник отделения опухолей головы и шеи

gribova79@mail.ruНовиковВ. А.NovikovV. A.

Новиков Валерий Александрович, доктор медицинских нак, ведущий научный сотрудник отделения опухолей головы и шеи

gribova79@mail.ruМусабаеваЛ. И.MusabayevaL. I.

Мусабаева Людмила Ивановна, доктор медицинских наук, главный научный сотрудник отделения радиологии

gribova79@mail.ruПолежаеваИ. С.PolezhayevaI. S.

Полежаева Ирина Сергеевна, ординатор отделения радиологии

gribova79@mail.ruНаучно-исследовательский институт онкологии Сибирского отделения РАМН, ТомскРоссияCancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, TomskRussian Federation201428062014133119125Copyright © Чойнзонов Е.Л., Грибова О.В., Старцева Ж.А., Рябова А.И., Новиков В.А., Мусабаева Л.И., Полежаева И.С., 20142014Чойнзонов Е.Л., Грибова О.В., Старцева Ж.А., Рябова А.И., Новиков В.А., Мусабаева Л.И., Полежаева И.С.Choinzonov Y.L., Gribova O.V., Startseva Z.A., Ryabova A.I., Novikov V.A., Musabayeva L.I., Polezhayeva I.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/73

Злокачественные глиомы (G III–IV по классификации Всемирной организации здравоохранения) составляют более 50% всех первичных опухолей головного мозга. Несмотря на достаточно агрессивную лечебную тактику, средняя продолжительность жизни больных этой патологией составляет 14 мес.Лучевая терапия является неотъемлемой частью комбинированного лечения, но зачастую не оказывает летального эффекта на резистентные опухолевые клетки. В связи с этим в последние десятилетия активно ведутся поиск и разработка новых подходов к лечению злокачественных глиом, среди них химиотерапевтические препараты, различные биологические модификаторы, в том числе локальная гипертермия (ЛГ). Экспериментальные данные показали, что действие высоких температур оказывает как прямое повреждающее действие на опухолевые клетки, так и сенсибилизирующий эффект. Значимые преимущества достигнуты при включении ЛГ в программы комплексного лечения злокачественных новообразований различных локализаций. Однако данные по лечению больных первичными и рецидивными глиомами G III–IV с применени ем локальной гипертермии малочисленны.В статье приводится обзор научных публикаций для ознакомления с существующими методами лечения злокачественных глиом головного мозга.

High-grade malignant gliomas (WHO grade G III–IV) account for more than 50% of all primary brain tumors. Despite aggressive treatment, survival rates are still very low with a median reported survival of no more than 1.5 years.Radiation therapy is an integral part of the combined treatment, but often does not influence lethally on resistant tumor cells. Thereby, in recent decades there has been an active search for novel approaches to the treatment of malignant gliomas (chemotherapeutic drugs, biological modifiers, local hyperthermia). Experimental data showed that the effect of high temperatures has both a direct damaging effect on tumor cells and a sensitizing effect. Significant advantages are achieved when the complex treatment of different malignant tumorsincludes local hyperthermia. However data on the treatment of patients with primary and recurrent gliomas G III–IV using local hyperthermia are scarce.The literature review is given in the article provides an overview of the existing treatment methods for brain tumors.

злокачественные глиомы головного мозгакомбинированное лечениехимиолучевая терапиялокальная гипертермияmalignant gliomascombined modality treatmentchemotherapylocal hyperthermiaReferencesБлисеева А.В. Злокачественные новообразования в России в 2009 г. (заболеваемость и смертность). М., 2010. 17 с.Bliseeva А.V. Cancerin Russiain 2009 (morbidity and mortality). Мoscow, 2010, p. 17 (in Russian).Мартынов Б.В. Метод стереотаксической криодеструкции в лечении больных с глиомами головного мозга // Вопросы нейрохирургии именени Н.Н. Бурденко. 2011. Т. 75. С. 17–24.Svistov D.V., Martynov B.V., Holjavin А.I. et al. Surgical resection combined with stereotactic cryodestruction in patients with supratentorial gliomas in functionally important regions of the brain: the ability of the combined surgical treatment and its results. Journal of Surgery of I.I. Grekov, 2012, vol. 171, no. 4, pp. 11–16 (in Russian).Свистов Д.В., Мартынов Б.В., Холявин А.И. и др. Хирургическая резекция в сочетании со стереотаксической криодеструкцией у больных с супратенториальными глиомами в функционально значимых областях мозга: возможность применени я комбинированного хирургического лечения и его результаты // Вестн. хирургии именени И.И. Грекова. 2012. Т. 171, № 4. С. 11–16.Van Meir E.G., Hadjipanayis C.G., Norden A.D. et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J. Clin., 2010, vol. 60, pp. 166–193.Van Meir E.G., Hadjipanayis C.G., Norden A.D. et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma // CA Cancer J. Clin. 2010. V. 60. P. 166–193.Martynov B.V. Method of stereotactic cryodestruction in the treatment of patients with cerebral gliomas. Journal of neurosurgery of N.N. Burdenko, 2011, vol. 75, pp. 17–24 (in Russian).Diez Valle R., Tejada Solis S., Idoate Gastearena M.A. et al. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in singlecenter experience // J. Neurooncol. 2011. V. 102. P. 105–113.Diez Valle R., Tejada Solis S., Idoate Gastearena M.A. et al. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in singlecenter experience. J. Neurooncol., 2011, vol. 102, pp. 105–113.Eyüpoglu I.Y., Hore N., Savaskan N.E. et al. Improving the extent of malignant glioma resection by dual intraoperative visualization approach [Electronic resourse] // PLOS ONE. 2012. V. 7(9). URL: http://www.plosone.org/article/info%3 Adoi%2F10.1371%2Fjournal.pone.0044885Eyüpoglu I.Y., Hore N., Savaskan N.E. et al. Improving the extent of malignant glioma resection by dual intraoperative visualization approach. PLOS ONE., 2012, vol. 7 (9). URL: http://www.plosone.org/article/info%3Adoi%2F10.1371%2F journal.pone.0044885Олюшин В.Е. Глиальные опухоли головного мозга: краткий обзор литературы и протокол лечения больных // Нейрохирургия. 2005. № 4. С. 41–47.Olyushin V.Е. Gliomas: brief literature review and treatment protocol. Neurosurgery, 2005, no. 4, pp. 41–47 (in Russian).McGirt M.J., Mukherjee D., Chaichana K.L. et al. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiform // Neurosurgery. 2009. V. 65. P. 463–469.McGirt M.J., Mukherjee D., Chaichana K.L. et al. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery, 2009, vol. 65, pp. 463–469.Насхлеташвили Д.Р., Бекяшев А.Х., Карахан В.Б. и др. Роль темозоломида в лечении глиобластом головного мозга // Опухоли головы и шеи. 2011. № 2. С. 34–35.Naschletashvili D.R., Bekyashev А.Kh., Karakhan V.B. et al. Role of temozolomide in treatment of malignant glioblastomas. Head and neck tumors, 2011, no. 2, pp. 34–35 (in Russian).Ростовцев Д.М., Олюшин В.Е., Папаян Г.В. и др. Фотодиагностика и фотодинамическая терапия в хирургии церебральных глиом. Опыт применени я // Рос. нейрохирург. журн. именени проф. А.Л. Поленова. 2012. Т. 4, № 4. С. 33–37.Rostovcev D.М., Oljushin V.Е., Papajan G.V. et al. Fotodiagnostics and photodynamic therapy of cerebral gliomas in surgery. Experience of using. Russian neurosurgical journal of prof. A.L. Polenov, 2012, vol. 4, no. 4, pp. 33–37 (in Russian).Bouchard P. Results of biopsy high-grade gliomas after highdose radiotherapy // Am. J. Clin. Oncol. 2000. V. 22 (1). P. 22–33.Bouchard P. Results of biopsy high-grade gliomas after highdose radiotherapy. Am. J. Clin. Oncol., 2000, vol. 22 (1), pp. 22–33.Смолин А.В. Комбинированная химиолучевая терапия при мультиформных глиобластомах ГВКГ именени Бурденко // Современные проблемы нейроонкологии: сборник трудов. М.: Изд-во РОНЦ РАМН, 2007. С. 25–31.Smolin А.V. Concurrent chemoradiation therapy for glioblastoma multiforme. Current problems of neurooncology. Collected papers. Мoscow, N.N. Blokhin RCRC RAMS press, 2007, pp. 25–31 (in Russian).Laperriere N., Zuraw L., Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review // Radiother. Oncol. 2002. V. 64. P. 259–273.Laperriere N., Zuraw L., Cairncross G. Radiotherapy fonewly diagnosed malignant glioma in adults: a systematic review. Radiother. Oncol., 2002, vol. 64, pp. 259–273.Chan J.L., Lee S.W., Fraas B.A. et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy // J. Clin. Oncol. 2002. V. 20. P. 1635–1642.Chan J.L., Lee S.W., Fraas B.A. et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J. Clin. Oncol., 2002, vol. 20, pp. 1635–1642.Dhermain F. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches // Chin. J. Cancer. 2014. V. 33(1). P. 16–24.Dhermain F. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches. Chin. J. Cancer., 2014, vol. 33 (1), pp. 16–24.Nieder C., Mehta M.P. Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma // Med. Hypotheses. 2011. V. 76 (3). P. 410–413.Nieder C., Mehta M.P. Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma. Med. Hypotheses, 2011, vol. 76 (3), pp. 410–413.Бенцион Д.Л. Совершенствование методов адъювантной терапии пациентов с мультиформной глиобластомой: автореф. дис. … кандидат медицинских наук. Уфа, 2011. 25 с.Bentsion D.L. Improvement of methods of adjuvant chemotherapy for patients with glioblastoma multiforme. Author. dis. cand. med. sci. Ufa, 2011. 25 p. (in Russian).Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials // Lancet. 2002. V. 359. P. 1011–1018.Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet, 2002, vol. 359, pp. 1011–1018.Thomas R.P., Recht L., Nagpal S. Advances in the management of glioblastoma: the role of temozolomide and MGMT testing // Clin. Pharmacol. 2013. V. 5. P. 1–9.Thomas R.P., Recht L., Nagpal S. Advances in the management of glioblastoma: the role of temozolomide and MGMT testing. Clin. Pharmacol., 2013, vol. 5, pp. 1–9.Stevens M.F., Hickman J.A., Stone R. et al. Antitumor imidazotetrazines. 1.Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl) imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, a novel broad-spectrum antitumor agent // J. Med. Chem. 1984. V. 27 (2). P. 196–201.Stevens M.F., Hickman J.A., Stone R. et al. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8- carbamoyl-3-(2-chloroethyl) imidazo[5,1-d]-1,2,3,5-tetrazin4(3H)-one, a novel broad-spectrum antitumor agent. J. Med. Chem., 1984, vol. 27 (2), pp. 196–201.Осинов И.К., Мусабаева Л.И., Нечитайло М.Н., Чойнзонов Е.Л. Химиолучевое лечение злокачественных глиом головного мозга с применени ем препарата темодал // Сиб. онкол. журн. 2009. № 6. С. 5–11.Osinov I.К., Musabaeva L.I., Nechitailo М.N., Choinzonov Е.L. Concurrent chemoradiation with temadol for malignant gliomas. Siberian Journal of Oncology, 2009, no. 6, pp. 5–11 (in Russian).Stupp R., Hegi M.E., Mason W.P. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial // Lancet Oncol. 2009. V. 10. P. 459–466.Stupp R., Hegi M.E., Mason W.P. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol., 2009, vol. 10, pp. 459–466.Purow B., Schiff D. Advances in the genetics of gliobla¬stoma: are we reaching critical mass? // Nat. Rev. Neurol. 2009. V. 5 (8). P. 419–426.Purow B., Schiff D. Advances in the genetics of glioblastoma: are we reaching critical mass? Nat. Rev. Neurol., 2009, vol. 5 (8), pp. 419–426.Villano J.L., Seery T.E., Bressler L.R. Temozolomide in malignant gliomas: current use and future targets // Cancer Chemother. Pharmacol. 2009. V. 64 (4). P. 647–655.Villano J.L., Seery T.E., Bressler L.R. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother. Pharmacol., 2009, vol. 64 (4), pp. 647–655.Niyazi M., Siefert A., Schwarz S.B. et al. Therapeutic options for recurrent malignant glioma // Radiother. Oncol. 2011. V. 98 (1). P. 1–14.Niyazi M., Siefert A., Schwarz S.B. et al. Therapeutic options for recurrent malignant glioma. Radiother Oncol., 2011, vol. 98 (1), pp. 1–14.Cecchi M., Vaiani M., Ceroti M. et al. A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma // Int. J. Clin. Pharm. 2013. V. 35(3). P. 483–487.Cecchi M., Vaiani M., Ceroti M. et al. A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma. Int. J. Clin. Pharm., 2013, vol. 35 (3), pp. 483–487.Lai A., Tran A., Nghiemphu P.L. et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme // J. Clin. Oncol. 2011. V. 29 (2). P. 142–148.Lai A., Tran A., Nghiemphu P.L. et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol., 2011, vol. 29 (2), pp. 142–148.Thon N., Kreth S., Kreth F. Personalized treatment strategies in glioblastoma: MGMT promoter methylation status // Onco. Targets Ther. 2013. V. 6. P. 1363–1372.Thon N., Kreth S., Kreth F. Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. Onco. Targets Ther., 2013, vol. 6, pp. 1363–1372.Дарьялова С.Л., Бойко А.В., Черниченко А.В. Расширение показаний к радикальному лечению больных с запущенными опухолями за счет использования противоопухолевых препаратов в качестве модификаторов при лучевой терапии // Тез. докл. Пленума правления Всерос. науч. мед. общества онкологов. Ростов н/Д, 1999. C. 196–198.Daryalova S.L., Boiko А.V., Chernichenko А.V. Extension of indications to radical treatment of patients with advanced cancer due to the use of anticancer drugs as modifiers of radiation therapy. Abstracts of the Plenum of the Boardofthe All-Russian Scientific Medical Society of Oncologists. Rostov-on-Don, 1999, pp. 196–198 (in Russian).Jeremic B., Shibamoto Y., Stanislavlievic B. et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial // Radiotherapy and Oncology. 1997. V. 43. P. 29–37.Jeremic B., Shibamoto Y., Stanislavlievic B. et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiotherapy and Oncology, 1997, vol. 43, pp. 29–37.Ярмоненко С.П., Вайнсон А.А. Радиобиология человека и животных. М.: Наука, 2004. 549 с.Yarmonenko S.P., Vainson А.А. Radiobiology of humans and animals. Мoscow, Science Publ., 2004. 549 p. (in Russian).Colombo R., Da Pozzo L.F., Salonia A. et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma // J. Clin. Oncol. 2003. V. 21. P. 4270–4276.Colombo R., Da Pozzo L.F., Salonia A. et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J. Clin. Oncol., 2003, vol. 21, pp. 4270–4276.Overgaard J., Gonzalez D.G., Hulshof M.C. et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre ran-domized trial by the European Society for Hyperthermic Oncology // Int. J. Hyperthermia. 1996. V. 12. P. 3–20.Overgaard J., Gonzalez D.G., Hulshof M.C. et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre ran-domized trial by the European Society for Hyperthermic Oncology. Int. J. Hyperthermia, 1996, vol. 12, pp. 3–20.Palazzi M., Maluta S., Dall'Oglio S., Romano M. The role of hyperthermia in the battle against cancer // Tumori. 2010. V. 96 (6). P. 902–910.Palazzi M., Maluta S., Dall'Oglio S., Romano M. The role of hyperthermia in the battle against cancer. Tumori, 2010, vol. 96 (6), pp. 902–910.Harima Y., Nagata K., Harima K. et al. A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIb cervical carcinoma // Int. J. Hyperthermia. 2001. V. 17. P. 97–105.Harima Y., Nagata K., Harima K. et al. A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIb cervical carcinoma. Int. J. Hyperthermia, 2001, vol. 17, pp. 97–105.Sneed P.K., Stauffer P.R., McDermott W. et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme // Int. J. Radiat. Oncol. Biol. Phys. 1998. V. 40. P. 287–295.Sneed P.K., Stauffer P.R., McDermott W. et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys., 1998, vol. 40, pp. 287–295.Issels R.D., Lindner L.H., Verweij J. et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localized high-risk soft-tissue sarcoma: a randomized phase 3 multicentre study // Lancet Oncol. 2010. V. 11 (6). P. 561–570.Issels R.D., Lindner L.H., Verweij J. et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localized high-risk soft-tissue sarcoma: a randomized phase 3 multicentre study. Lancet Oncol., 2010, vol. 11 (6), pp. 561–570.Maluta S., Dall'oglio S., Nadalini L. Treatment for intermediate and high-risk prostate cancer: controversial issues and the role of hyperthermia // Int. J. Hyperthermia. 2010. V. 26 (8). P. 765–774.Maluta S., Dall'oglio S., Nadalini L. Treatment for intermediate and high-risk prostate cancer: controversial issues and the role of hyperthermia. Int. J. Hyperthermia, 2010, vol. 26 (8), pp. 765–774.Strotsky A.V., Fradkin S.Z., Zhavrid E.A. et al. Combined therapy of bladder cancer with the use of hyperthermia // Strahlenther Onkol. 1991. V. 167. P. 346.Strotsky A.V., Fradkin S.Z., Zhavrid E.A. et al. Combined therapy of bladder cancer with the use of hyperthermia. Strahlenther Onkol., 1991, vol. 167, p. 346.Maluta S., Romano M., Dall'oglio S. et al. Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum // Int. J. Hyperthermia. 2010. V. 26 (2). P. 108–117.Maluta S., Romano M., Dall'oglio S. et al. Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum. Int. J. Hyperthermia, 2010, vol. 26 (2), pp. 108–117.Maluta S., Schaffer M., Pioli F. et al. Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer: an open-label comparative cohort trial // Strahlenther Onkol. 2011. V. 187 (10). P. 619–625.Maluta S., Schaffer M., Pioli F. et al. Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer: an open-label comparative cohort trial. Strahlenther Onkol., 2011, vol. 187 (10), pp. 619–625.Wang J., Li D., Chen N. Intracavitary microwave hyperthermia combined with external irradiation in the treatment of esophageal cancer // Zhonghua Zhong Liu Za Zhi. 1996. V. 18. P. 51–54.Wang J., Li D., Chen N. Intracavitary microwave hyperthermia combined with external irradiation in the treatment of esophageal cancer. Zhonghua Zhong Liu Za Zhi, 1996, vol. 18, pp. 51–54.Egawa S., Tsukiyama I., Watanabe S. et al. A randomized clinical trial of hyperthermia and radiation versus radiation alone for superficially located cancers // J. Jpn. Soc. Ther. Radiol. Oncol. 1989. V. 1. P. 135–140.Egawa S., Tsukiyama I., Watanabe S. et al. A randomized clinical trial of hyperthermia and radiation versus radiation alone for superficially located cancers. J. Jpn. Soc. Ther. Radiol. Oncol., 1989, vol. 1, pp. 135–140.Dahl O., Mella O. Enhanced effect of combined hyperthermia and chemotherapy (bleomycin, BCNU) in a neurogenic rat tumour (BT4A) in vivo // Anticancer. Res. 1982. V. 2. P. 359–364.Dahl O., Mella O. Enhanced effect of combined hyperthermia and chemotherapy (bleomycin, BCNU) in a neurogenic rat tumour (BT4A) in vivo. Anticancer Res., 1982, vol. 2, pp. 359–364.Gorter R. Patienten mit Glioblastoma multiforme Grad IV, die im MCC von 01/2003 bis 02/2010 mit lokaler Hyperthermie (Celsius 42+) und Dendritischen Zellen behandelt wurden // IV Hyperthermie Symposium. Absracts. 2013. P. 12–14.Gorter R. Patienten mit Glioblastoma multiforme Grad IV, die im MCC von 01/2003 bis 02/2010 mit lokaler Hyperthermie (Celsius 42+) und Dendritischen Zellen behandelt wurden. IV Hyperthermie Symposium. Absracts, 2013, pp. 12–14.

The authors declare that there are no conflicts of interest present.